JP2010509402A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509402A5 JP2010509402A5 JP2009537305A JP2009537305A JP2010509402A5 JP 2010509402 A5 JP2010509402 A5 JP 2010509402A5 JP 2009537305 A JP2009537305 A JP 2009537305A JP 2009537305 A JP2009537305 A JP 2009537305A JP 2010509402 A5 JP2010509402 A5 JP 2010509402A5
- Authority
- JP
- Japan
- Prior art keywords
- chlorophenyl
- methyl
- amino
- methanone
- thiophen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 28
- FHMKBGPASICGMG-UHFFFAOYSA-N [2-amino-4-[[4-(3-fluorophenyl)piperazin-1-yl]methyl]-5-methylthiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=C(F)C=CC=2)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 FHMKBGPASICGMG-UHFFFAOYSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 239000001257 hydrogen Substances 0.000 claims 32
- 150000002431 hydrogen Chemical class 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000003107 substituted aryl group Chemical group 0.000 claims 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 239000001301 oxygen Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 4
- 208000019622 heart disease Diseases 0.000 claims 4
- 229910052717 sulfur Chemical group 0.000 claims 4
- 239000011593 sulfur Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 3
- 101150007969 ADORA1 gene Proteins 0.000 claims 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- MLBNYNHTFZBWOO-UHFFFAOYSA-N [2-amino-4-[(4-cyclopentylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1CCCC1 MLBNYNHTFZBWOO-UHFFFAOYSA-N 0.000 claims 2
- WBVSHKCZLDSJBP-UHFFFAOYSA-N [2-amino-4-[(4-phenylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=CC=C1 WBVSHKCZLDSJBP-UHFFFAOYSA-N 0.000 claims 2
- WTJJQPAIMDOFHJ-UHFFFAOYSA-N [2-amino-4-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(Cl)C=C1 WTJJQPAIMDOFHJ-UHFFFAOYSA-N 0.000 claims 2
- PIGHLLPGQFTIDD-UHFFFAOYSA-N [2-amino-4-[[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 PIGHLLPGQFTIDD-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- WGSAKPFHJLTQFG-UHFFFAOYSA-N 1-[4-[[5-amino-4-(4-chlorobenzoyl)thiophen-3-yl]methyl]piperazin-1-yl]-2-(4-chlorophenyl)ethanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C(=O)CC1=CC=C(Cl)C=C1 WGSAKPFHJLTQFG-UHFFFAOYSA-N 0.000 claims 1
- BTURCFCECILJTE-UHFFFAOYSA-N 2-[4-[[5-amino-4-(4-chlorobenzoyl)thiophen-3-yl]methyl]piperazin-1-yl]-1-(4-chlorophenyl)ethanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1CC(=O)C1=CC=C(Cl)C=C1 BTURCFCECILJTE-UHFFFAOYSA-N 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- ITIPXEQVFANBBI-UHFFFAOYSA-N 4-[4-[[5-amino-4-(4-chlorobenzoyl)-2-methylthiophen-3-yl]methyl]piperazin-1-yl]benzonitrile Chemical compound C1CN(C=2C=CC(=CC=2)C#N)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 ITIPXEQVFANBBI-UHFFFAOYSA-N 0.000 claims 1
- GBEKMUYDTMZKOO-UHFFFAOYSA-N 4-[4-[[5-amino-4-(4-chlorobenzoyl)thiophen-3-yl]methyl]piperazin-1-yl]benzonitrile Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(C#N)C=C1 GBEKMUYDTMZKOO-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- LGTDDJCWKVBENO-UHFFFAOYSA-N [2-amino-4-(spiro[1,3-benzodioxole-2,4'-piperidine]-1'-ylmethyl)thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound NC=1SC=C(CN2CCC3(CC2)OC2=CC=CC=C2O3)C=1C(=O)C1=CC=C(Cl)C=C1 LGTDDJCWKVBENO-UHFFFAOYSA-N 0.000 claims 1
- HYXHXEHHOZDASV-UHFFFAOYSA-N [2-amino-4-[(4-benzylpiperazin-1-yl)methyl]-5-methylthiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(CC=2C=CC=CC=2)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 HYXHXEHHOZDASV-UHFFFAOYSA-N 0.000 claims 1
- VLUIIUMESZDQJJ-UHFFFAOYSA-N [2-amino-4-[(4-benzylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1CC1=CC=CC=C1 VLUIIUMESZDQJJ-UHFFFAOYSA-N 0.000 claims 1
- PNTFMBLZDHRWEH-UHFFFAOYSA-N [2-amino-4-[(4-cyclohexylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1CCCCC1 PNTFMBLZDHRWEH-UHFFFAOYSA-N 0.000 claims 1
- GZDAZWLRSGSJFO-UHFFFAOYSA-N [2-amino-4-[(4-cyclooctylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1CCCCCCC1 GZDAZWLRSGSJFO-UHFFFAOYSA-N 0.000 claims 1
- UUYUBKMEGGSUJJ-UHFFFAOYSA-N [2-amino-4-[(4-fluorospiro[1,3-benzodioxole-2,4'-piperidine]-1'-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound NC=1SC=C(CN2CCC3(CC2)OC2=C(F)C=CC=C2O3)C=1C(=O)C1=CC=C(Cl)C=C1 UUYUBKMEGGSUJJ-UHFFFAOYSA-N 0.000 claims 1
- FBLJFWZLJFATLC-UHFFFAOYSA-N [2-amino-4-[(4-methylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C)CCN1CC1=CSC(N)=C1C(=O)C1=CC=C(Cl)C=C1 FBLJFWZLJFATLC-UHFFFAOYSA-N 0.000 claims 1
- FVCNDFNVEXZHJO-UHFFFAOYSA-N [2-amino-4-[(4-methylspiro[1,3-benzodioxole-2,4'-piperidine]-1'-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound O1C=2C(C)=CC=CC=2OC1(CC1)CCN1CC1=CSC(N)=C1C(=O)C1=CC=C(Cl)C=C1 FVCNDFNVEXZHJO-UHFFFAOYSA-N 0.000 claims 1
- RITYNZBWVKWGFS-UHFFFAOYSA-N [2-amino-4-[(4-naphthalen-1-ylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound NC=1SC=C(CN2CCN(CC2)C=2C3=CC=CC=C3C=CC=2)C=1C(=O)C1=CC=C(Cl)C=C1 RITYNZBWVKWGFS-UHFFFAOYSA-N 0.000 claims 1
- ZTWZRYZHIXOGES-UHFFFAOYSA-N [2-amino-4-[(4-propan-2-ylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C(C)C)CCN1CC1=CSC(N)=C1C(=O)C1=CC=C(Cl)C=C1 ZTWZRYZHIXOGES-UHFFFAOYSA-N 0.000 claims 1
- LRNXGDCNTQAXDV-UHFFFAOYSA-N [2-amino-4-[(4-pyridin-2-ylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=CC=N1 LRNXGDCNTQAXDV-UHFFFAOYSA-N 0.000 claims 1
- JKXQLDDFLKSYTM-UHFFFAOYSA-N [2-amino-4-[(4-pyridin-3-ylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=CN=C1 JKXQLDDFLKSYTM-UHFFFAOYSA-N 0.000 claims 1
- PTDILEGANSBTSE-UHFFFAOYSA-N [2-amino-4-[(4-pyridin-4-ylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=NC=C1 PTDILEGANSBTSE-UHFFFAOYSA-N 0.000 claims 1
- FJHGONQMXVSBES-UHFFFAOYSA-N [2-amino-4-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=NC=CC=N1 FJHGONQMXVSBES-UHFFFAOYSA-N 0.000 claims 1
- VGTGXMREKQFXNQ-UHFFFAOYSA-N [2-amino-4-[(5-methylspiro[1,3-benzodioxole-2,4'-piperidine]-1'-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound O1C2=CC(C)=CC=C2OC1(CC1)CCN1CC1=CSC(N)=C1C(=O)C1=CC=C(Cl)C=C1 VGTGXMREKQFXNQ-UHFFFAOYSA-N 0.000 claims 1
- LXZNFZIWNXAXPF-UHFFFAOYSA-N [2-amino-4-[(5-tert-butylspiro[1,3-benzodioxole-2,4'-piperidine]-1'-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound O1C2=CC(C(C)(C)C)=CC=C2OC1(CC1)CCN1CC1=CSC(N)=C1C(=O)C1=CC=C(Cl)C=C1 LXZNFZIWNXAXPF-UHFFFAOYSA-N 0.000 claims 1
- BKVQQVAZXXNRAL-UHFFFAOYSA-N [2-amino-4-[[2-(4-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptan-5-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN1CC2CC1CN2C1=CC=C(Cl)C=C1 BKVQQVAZXXNRAL-UHFFFAOYSA-N 0.000 claims 1
- XEJIHQOMTYJWCT-UHFFFAOYSA-N [2-amino-4-[[2-(4-chlorophenyl)-2,7-diazaspiro[4.4]nonan-7-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(C1)CCC1(C1)CCN1C1=CC=C(Cl)C=C1 XEJIHQOMTYJWCT-UHFFFAOYSA-N 0.000 claims 1
- VETJLOKKGTWBFO-UHFFFAOYSA-N [2-amino-4-[[4-(1,3-benzodioxol-5-yl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound NC=1SC=C(CN2CCN(CC2)C=2C=C3OCOC3=CC=2)C=1C(=O)C1=CC=C(Cl)C=C1 VETJLOKKGTWBFO-UHFFFAOYSA-N 0.000 claims 1
- BRWGCTMCYZVICL-UHFFFAOYSA-N [2-amino-4-[[4-(2,3-dichlorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=CC(Cl)=C1Cl BRWGCTMCYZVICL-UHFFFAOYSA-N 0.000 claims 1
- SKVYUUPKEQJOOR-UHFFFAOYSA-N [2-amino-4-[[4-(2,3-difluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=CC(F)=C1F SKVYUUPKEQJOOR-UHFFFAOYSA-N 0.000 claims 1
- QLXKABIMWDIRKB-UHFFFAOYSA-N [2-amino-4-[[4-(2,4,6-trifluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=C(F)C=C(F)C=C1F QLXKABIMWDIRKB-UHFFFAOYSA-N 0.000 claims 1
- RLQCJMVZVOGKBW-UHFFFAOYSA-N [2-amino-4-[[4-(2,4-dichlorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(Cl)C=C1Cl RLQCJMVZVOGKBW-UHFFFAOYSA-N 0.000 claims 1
- VUSWZWCZLQPKBC-UHFFFAOYSA-N [2-amino-4-[[4-(2,4-difluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(F)C=C1F VUSWZWCZLQPKBC-UHFFFAOYSA-N 0.000 claims 1
- RRXKFDQOOZHJTF-UHFFFAOYSA-N [2-amino-4-[[4-(2,5-dichlorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC(Cl)=CC=C1Cl RRXKFDQOOZHJTF-UHFFFAOYSA-N 0.000 claims 1
- DXGZCDTWBDRRKI-UHFFFAOYSA-N [2-amino-4-[[4-(2,5-difluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC(F)=CC=C1F DXGZCDTWBDRRKI-UHFFFAOYSA-N 0.000 claims 1
- BHNZEYVIYRIQCZ-UHFFFAOYSA-N [2-amino-4-[[4-(2,6-dichlorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=C(Cl)C=CC=C1Cl BHNZEYVIYRIQCZ-UHFFFAOYSA-N 0.000 claims 1
- DHAUTGJWCQUFII-UHFFFAOYSA-N [2-amino-4-[[4-(2,6-difluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=C(F)C=CC=C1F DHAUTGJWCQUFII-UHFFFAOYSA-N 0.000 claims 1
- HDQFEKGOVIJERJ-UHFFFAOYSA-N [2-amino-4-[[4-(2,6-difluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-[3-(trifluoromethyl)phenyl]methanone Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=C(F)C=CC=C1F HDQFEKGOVIJERJ-UHFFFAOYSA-N 0.000 claims 1
- FJERGVLETHXCBK-UHFFFAOYSA-N [2-amino-4-[[4-(2-chloro-4-fluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(F)C=C1Cl FJERGVLETHXCBK-UHFFFAOYSA-N 0.000 claims 1
- ZGNUUPGCNLNRGC-UHFFFAOYSA-N [2-amino-4-[[4-(2-chlorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=CC=C1Cl ZGNUUPGCNLNRGC-UHFFFAOYSA-N 0.000 claims 1
- KFWAXNAVBQKIAZ-UHFFFAOYSA-N [2-amino-4-[[4-(2-fluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=CC=C1F KFWAXNAVBQKIAZ-UHFFFAOYSA-N 0.000 claims 1
- NQOCPHPCHPECPX-UHFFFAOYSA-N [2-amino-4-[[4-(3,4-dichlorophenyl)piperazin-1-yl]methyl]-5-methylthiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=C(Cl)C(Cl)=CC=2)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 NQOCPHPCHPECPX-UHFFFAOYSA-N 0.000 claims 1
- HZIBFSCCTZORDE-UHFFFAOYSA-N [2-amino-4-[[4-(3,4-dichlorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(Cl)C(Cl)=C1 HZIBFSCCTZORDE-UHFFFAOYSA-N 0.000 claims 1
- RQMCCXLNHOFIBT-UHFFFAOYSA-N [2-amino-4-[[4-(3,4-difluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(F)C(F)=C1 RQMCCXLNHOFIBT-UHFFFAOYSA-N 0.000 claims 1
- ACGNVIYHWCNNLW-UHFFFAOYSA-N [2-amino-4-[[4-(3,5-dichlorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC(Cl)=CC(Cl)=C1 ACGNVIYHWCNNLW-UHFFFAOYSA-N 0.000 claims 1
- UFSBQTGZKIHMDQ-UHFFFAOYSA-N [2-amino-4-[[4-(3,5-difluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC(F)=CC(F)=C1 UFSBQTGZKIHMDQ-UHFFFAOYSA-N 0.000 claims 1
- KFWLBGALSCQPIL-UHFFFAOYSA-N [2-amino-4-[[4-(3-chloro-4-fluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(F)C(Cl)=C1 KFWLBGALSCQPIL-UHFFFAOYSA-N 0.000 claims 1
- WERJSQBLFNLURF-UHFFFAOYSA-N [2-amino-4-[[4-(3-chlorophenyl)piperazin-1-yl]methyl]-5-methylthiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=C(Cl)C=CC=2)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 WERJSQBLFNLURF-UHFFFAOYSA-N 0.000 claims 1
- NDWVFXKAKMRXDA-UHFFFAOYSA-N [2-amino-4-[[4-(3-chlorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=CC(Cl)=C1 NDWVFXKAKMRXDA-UHFFFAOYSA-N 0.000 claims 1
- ALBMIWSWBYYXEY-UHFFFAOYSA-N [2-amino-4-[[4-(3-fluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=CC(F)=C1 ALBMIWSWBYYXEY-UHFFFAOYSA-N 0.000 claims 1
- GNWFQOVRVPCKAX-UHFFFAOYSA-N [2-amino-4-[[4-(3-fluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-[3-(trifluoromethyl)phenyl]methanone Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=CC(F)=C1 GNWFQOVRVPCKAX-UHFFFAOYSA-N 0.000 claims 1
- MMICKMTWNXSUED-UHFFFAOYSA-N [2-amino-4-[[4-(4-bromophenyl)piperazin-1-yl]methyl]-5-methylthiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=CC(Br)=CC=2)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 MMICKMTWNXSUED-UHFFFAOYSA-N 0.000 claims 1
- MVAJEYSIMFZYTH-UHFFFAOYSA-N [2-amino-4-[[4-(4-chloro-2-fluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(Cl)C=C1F MVAJEYSIMFZYTH-UHFFFAOYSA-N 0.000 claims 1
- LGEOYUJLUUMXMY-UHFFFAOYSA-N [2-amino-4-[[4-(4-chloroanilino)piperidin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCC1NC1=CC=C(Cl)C=C1 LGEOYUJLUUMXMY-UHFFFAOYSA-N 0.000 claims 1
- DFDQPGWWASNUFZ-UHFFFAOYSA-N [2-amino-4-[[4-(4-chlorobenzoyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C(=O)C1=CC=C(Cl)C=C1 DFDQPGWWASNUFZ-UHFFFAOYSA-N 0.000 claims 1
- WNMUAILZTTXQCU-UHFFFAOYSA-N [2-amino-4-[[4-(4-chlorophenyl)-1,4-diazepan-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCCN1C1=CC=C(Cl)C=C1 WNMUAILZTTXQCU-UHFFFAOYSA-N 0.000 claims 1
- LQCHGYZMZWGLMB-UHFFFAOYSA-N [2-amino-4-[[4-(4-chlorophenyl)-3-methylpiperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=CC(Cl)=CC=2)C(C)CN1CC1=CSC(N)=C1C(=O)C1=CC=C(Cl)C=C1 LQCHGYZMZWGLMB-UHFFFAOYSA-N 0.000 claims 1
- YTSDAHZZAZSJJB-UHFFFAOYSA-N [2-amino-4-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-5-ethylthiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=CC(Cl)=CC=2)CCN1CC1=C(CC)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 YTSDAHZZAZSJJB-UHFFFAOYSA-N 0.000 claims 1
- MKNILBHXNSANDH-UHFFFAOYSA-N [2-amino-4-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-5-methylthiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=CC(Cl)=CC=2)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 MKNILBHXNSANDH-UHFFFAOYSA-N 0.000 claims 1
- VQGCSQVHKQRFTI-UHFFFAOYSA-N [2-amino-4-[[4-(4-chlorophenyl)piperidin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCC1C1=CC=C(Cl)C=C1 VQGCSQVHKQRFTI-UHFFFAOYSA-N 0.000 claims 1
- VMLCVTIAPHRDMD-UHFFFAOYSA-N [2-amino-4-[[4-(4-fluorophenyl)piperazin-1-yl]methyl]-5-methylthiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=CC(F)=CC=2)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 VMLCVTIAPHRDMD-UHFFFAOYSA-N 0.000 claims 1
- KYYXRPCNRQBMKL-UHFFFAOYSA-N [2-amino-4-[[4-(4-fluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(F)C=C1 KYYXRPCNRQBMKL-UHFFFAOYSA-N 0.000 claims 1
- ZKWSINKFKJPGQH-UHFFFAOYSA-N [2-amino-4-[[4-(4-iodophenyl)piperazin-1-yl]methyl]-5-methylthiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=CC(I)=CC=2)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 ZKWSINKFKJPGQH-UHFFFAOYSA-N 0.000 claims 1
- GTPCHQHXBLWZKO-UHFFFAOYSA-N [2-amino-4-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-5-methylthiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1=CC(OC)=CC=C1N1CCN(CC=2C(=C(N)SC=2C)C(=O)C=2C=CC(Cl)=CC=2)CC1 GTPCHQHXBLWZKO-UHFFFAOYSA-N 0.000 claims 1
- CTRYPUGODHJJOD-UHFFFAOYSA-N [2-amino-4-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1=CC(OC)=CC=C1N1CCN(CC=2C(=C(N)SC=2)C(=O)C=2C=CC(Cl)=CC=2)CC1 CTRYPUGODHJJOD-UHFFFAOYSA-N 0.000 claims 1
- QQBFTEIZJXNNOZ-UHFFFAOYSA-N [2-amino-4-[[4-(4-methylphenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1=CC(C)=CC=C1N1CCN(CC=2C(=C(N)SC=2)C(=O)C=2C=CC(Cl)=CC=2)CC1 QQBFTEIZJXNNOZ-UHFFFAOYSA-N 0.000 claims 1
- JXLRWJMBKLELNA-UHFFFAOYSA-N [2-amino-4-[[4-(4-nitrophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C([N+]([O-])=O)C=C1 JXLRWJMBKLELNA-UHFFFAOYSA-N 0.000 claims 1
- QPOPDJJHKWFMOW-UHFFFAOYSA-N [2-amino-4-[[4-[(4-chlorophenyl)methyl]piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1CC1=CC=C(Cl)C=C1 QPOPDJJHKWFMOW-UHFFFAOYSA-N 0.000 claims 1
- DZGCVGMLWHAEKM-UHFFFAOYSA-N [2-amino-4-[[4-[(4-fluorophenyl)methyl]piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1CC1=CC=C(F)C=C1 DZGCVGMLWHAEKM-UHFFFAOYSA-N 0.000 claims 1
- ZGXZMEGSHAZRAK-UHFFFAOYSA-N [2-amino-4-[[4-[2-(4-chlorophenyl)ethyl]piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1CCC1=CC=C(Cl)C=C1 ZGXZMEGSHAZRAK-UHFFFAOYSA-N 0.000 claims 1
- RXDAZSCENDGBDL-UHFFFAOYSA-N [2-amino-4-[[4-[2-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=CC=C1C(F)(F)F RXDAZSCENDGBDL-UHFFFAOYSA-N 0.000 claims 1
- IIEVNVFDTPPXOR-UHFFFAOYSA-N [2-amino-4-[[4-[3-(4-chlorophenyl)propyl]piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1CCCC1=CC=C(Cl)C=C1 IIEVNVFDTPPXOR-UHFFFAOYSA-N 0.000 claims 1
- NIWKJXXHKUGXMO-UHFFFAOYSA-N [2-amino-4-[[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 NIWKJXXHKUGXMO-UHFFFAOYSA-N 0.000 claims 1
- JDVSMSUWNCGANW-UHFFFAOYSA-N [2-amino-4-[[4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(OC(F)(F)F)C=C1 JDVSMSUWNCGANW-UHFFFAOYSA-N 0.000 claims 1
- SKWGRGVAIYNYJB-UHFFFAOYSA-N [2-amino-4-[[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]thiophen-3-yl]-[3-(trifluoromethyl)phenyl]methanone Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 SKWGRGVAIYNYJB-UHFFFAOYSA-N 0.000 claims 1
- UJVLYPXHZKMJDT-UHFFFAOYSA-N [2-amino-4-[[4-[4-chloro-3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]-5-methylthiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 UJVLYPXHZKMJDT-UHFFFAOYSA-N 0.000 claims 1
- KRHSLCQRUAKMQG-UHFFFAOYSA-N [2-amino-4-[[4-[4-chloro-3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1)CCN1C1=CC=C(Cl)C(C(F)(F)F)=C1 KRHSLCQRUAKMQG-UHFFFAOYSA-N 0.000 claims 1
- LBKAZXGAYDUIRC-UHFFFAOYSA-N [2-amino-4-[[5-(4-chlorophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC=C1CN(CC1C2)CC1CN2C1=CC=C(Cl)C=C1 LBKAZXGAYDUIRC-UHFFFAOYSA-N 0.000 claims 1
- NMTPEPMKHPKCNG-UHFFFAOYSA-N [2-amino-5-ethyl-4-[(4-phenylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=CC=CC=2)CCN1CC1=C(CC)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 NMTPEPMKHPKCNG-UHFFFAOYSA-N 0.000 claims 1
- HLQHCKAEUVYEJJ-UHFFFAOYSA-N [2-amino-5-ethyl-4-[[4-(4-fluorophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=CC(F)=CC=2)CCN1CC1=C(CC)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 HLQHCKAEUVYEJJ-UHFFFAOYSA-N 0.000 claims 1
- IUSKEAVVZQVOIW-UHFFFAOYSA-N [2-amino-5-methyl-4-[(4-phenylpiperazin-1-yl)methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=CC=CC=2)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 IUSKEAVVZQVOIW-UHFFFAOYSA-N 0.000 claims 1
- SCFLUABYVYMZII-UHFFFAOYSA-N [2-amino-5-methyl-4-[[4-(4-methylphenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=CC(C)=CC=2)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 SCFLUABYVYMZII-UHFFFAOYSA-N 0.000 claims 1
- LLZNEOSUOOMOND-UHFFFAOYSA-N [2-amino-5-methyl-4-[[4-(4-nitrophenyl)piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=CC(=CC=2)[N+]([O-])=O)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 LLZNEOSUOOMOND-UHFFFAOYSA-N 0.000 claims 1
- KMGBMOJTGYSBOJ-UHFFFAOYSA-N [2-amino-5-methyl-4-[[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=C(C=CC=2)C(F)(F)F)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 KMGBMOJTGYSBOJ-UHFFFAOYSA-N 0.000 claims 1
- FIGZTXRYICMUIF-UHFFFAOYSA-N [2-amino-5-methyl-4-[[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(C=2C=CC(=CC=2)C(F)(F)F)CCN1CC1=C(C)SC(N)=C1C(=O)C1=CC=C(Cl)C=C1 FIGZTXRYICMUIF-UHFFFAOYSA-N 0.000 claims 1
- ZJXZMWGZHYTTGI-UHFFFAOYSA-N [2-amino-5-phenyl-4-(piperidin-1-ylmethyl)thiophen-3-yl]-(4-chlorophenyl)methanone Chemical compound C=1C=C(Cl)C=CC=1C(=O)C1=C(N)SC(C=2C=CC=CC=2)=C1CN1CCCCC1 ZJXZMWGZHYTTGI-UHFFFAOYSA-N 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102000009346 Adenosine receptors Human genes 0.000 description 4
- 108050000203 Adenosine receptors Proteins 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
- 102000055025 Adenosine deaminases Human genes 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 2
- 229950005741 rolipram Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- 0 C*c1c(C*(CC2*)CC(*)C22Oc3ccccc3O2)c(C(c2cc(*C)c(*)c(*)c2)=O)c(*C)[n]1 Chemical compound C*c1c(C*(CC2*)CC(*)C22Oc3ccccc3O2)c(C(c2cc(*C)c(*)c(*)c2)=O)c(*C)[n]1 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Description
ヒト組み換えA 1 、A 2A 及びA 3 アデノシン受容体でトランスフェクトしたCHO細胞からの膜調製物
hCHO−A1、hCHO−A2A及びhCHO−A3 の細胞クローンを粘性培養して、10%のウシ胎仔血清、ペニシリン(100U/mL)、ストレプトマイシン(100μg/mL)、L−グルタミン(2mM)、ゲネチシン(G418;0.2mg/mL)を含有する、栄養混合物F12を含むダルベッコ改変イーグル培地中で、5%CO2/95%空気中、37℃で保持した(Klots et al., Naunyn-Schmied. Arch Pharm. 1988, 357, 1-9)。細胞を1:5〜1:10の比率で週に2回又は3回分割する。膜調製物用に、培養培地を取り除く。細胞をPBSで洗浄して、氷冷低張緩衝液(5mMのトリス塩酸、2mMのEDTA、pH7.4)中でT75フラスコからこそげ取る。細胞浮遊液をポリトロンでホモジナイズして、ホモジネートを1,000×gで10分間回転させる。次いで上清を100,000×gで30分間遠心分離する。膜ペレットを、A1アデノシン受容体については50mMトリス塩酸緩衝液(pH7.4)に、A2Aアデノシン受容体については50mMトリス塩酸緩衝液(pH7.4、10mMのMgCl2)に、A3アデノシン受容体については50mMトリス塩酸緩衝液(pH7.4、10mMのMgCl2、1mMのEDTA)に再懸濁して、3UI/mLのアデノシンデアミナーゼと共に37℃で30分間培養する。タンパク濃度を、Bio−Rad法(Bradford, 1976)に従って、ウシアルブミンを標準的基準として測定する。
Cell clones of membrane preparations hCHO-A 1 , hCHO-A 2A and hCHO-A 3 from CHO cells transfected with human recombinant A 1 , A 2A and A 3 adenosine receptors were viscous cultured to 10% In Dulbecco's modified Eagle medium containing nutrient mixture F12 containing fetal calf serum, penicillin (100 U / mL), streptomycin (100 μg / mL), L-glutamine (2 mM), geneticin (G418; 0.2 mg / mL) Maintained at 37 ° C. in 5% CO 2 /95% air (Klots et al., Naunyn-Schmied. Arch Pharm. 1988, 357, 1-9). Cells are split twice or three times a week at a ratio of 1: 5 to 1:10. Remove culture medium for membrane preparation. Cells are washed with PBS and scraped from T75 flasks in ice-cold hypotonic buffer (5 mM Tris-HCl, 2 mM EDTA, pH 7.4). The cell suspension is homogenized with a polytron and the homogenate is spun at 1,000 × g for 10 minutes. The supernatant is then centrifuged at 100,000 × g for 30 minutes. The membrane pellet, 50 mM Tris-HCl buffer for A 1 adenosine receptor (pH 7.4), 50 mM Tris-HCl buffer for A 2A adenosine receptor (MgCl 2 in pH 7.4, 10 mM), A 3 adenosine The receptor is resuspended in 50 mM Tris-HCl buffer (pH 7.4, 10 mM MgCl 2 , 1 mM EDTA) and incubated with 3 UI / mL adenosine deaminase at 37 ° C. for 30 minutes. Protein concentration is measured according to the Bio-Rad method (Bradford, 1976) with bovine albumin as a standard reference.
CHO細胞におけるcAMP増強の測定(機能アッセイ)
アロステリックな増強を、異なった濃度(0.01、0.1、1及び10μM)の試験化合物がhCHO−A1細胞のcAMP含量を減少する作用として測定する。実験を始めるために、生育培地を12ウェルプレートから除去して、細胞を温かいハンクス緩衝食塩液で洗浄する。次いで洗浄溶液を除去して、ホルスコリン(1μM)、ロリプラム(20μM)、N6−シクロペンチルアデノシン(CPA、0.01nM)、アデノシンデアミナーゼ(2U/mL)、及び試験化合物を含有する新鮮なハンクス溶液と取り替える。ホルスコリンはアデニリルシクラーゼの活性を刺激するために、ロリプラムはcAMPホスホジエステラーゼを阻害するために、アデノシンデアミナーゼは内在性アデノシンを分解するために、そしてCPAは活性化アデノシン受容体数の微増をもたらすために用いる。試験化合物の存在下に、36℃で6分間培養した後、培養溶液を除去して、塩酸(最終濃度50mM)を薬物の作用を止めるために加える。細胞の酸性化抽出液cAMPの含量を既述(Kollias-Baker et al., J. Pharmacol. Exp. Ther. 1997, 281, 761-768)のようにしてラジオイムノアッセイで測定する。hCHO−A1細胞に対するアロステリックな調節効果の大きさが、継代数で微妙に変化して細胞の異なったアリコートの間で僅かに異なるので、試験化合物の作用及び対照化合物(PD81,723)の作用を、それぞれ実験で評価する。cAMP含量に対する各試験化合物の効果を、薬剤の非存在下(対照、100%)におけるcAMP含量の値のパーセントとして示す。
Measurement of cAMP enhancement in CHO cells (functional assay )
Allosteric enhancement is measured as the effect of different concentrations (0.01, 0.1, 1 and 10 μM) of the test compound on reducing the cAMP content of hCHO-A 1 cells. To begin the experiment, the growth medium is removed from the 12-well plate and the cells are washed with warm Hanks buffered saline. The washing solution is then removed and a fresh Hanks solution containing forskolin (1 μM), rolipram (20 μM), N 6 -cyclopentyladenosine (CPA, 0.01 nM), adenosine deaminase (2 U / mL), and test compound replace. Forskolin stimulates adenylyl cyclase activity, rolipram inhibits cAMP phosphodiesterase, adenosine deaminase degrades endogenous adenosine, and CPA causes a slight increase in the number of activated adenosine receptors Used for. After 6 minutes of incubation at 36 ° C. in the presence of the test compound, the culture solution is removed and hydrochloric acid (final concentration 50 mM) is added to stop the action of the drug. The content of the cell acidified extract cAMP is measured by radioimmunoassay as described previously (Kollias-Baker et al., J. Pharmacol. Exp. Ther. 1997, 281, 761-768). Since the magnitude of the allosteric regulatory effect on hCHO-A 1 cells varies slightly with the passage number and varies slightly between different aliquots of the cells, the effect of the test compound and the effect of the control compound (PD81,723) Are evaluated experimentally. The effect of each test compound on cAMP content is shown as a percentage of the value of cAMP content in the absence of drug (control, 100%).
{2−アミノ−4−[(4−(3−フルオロフェニル)ピペラジン−1−イル)メチル]−5−メチルチオフェン−3−イル}(4−クロロフェニル)メタノン {2-Amino-4-[(4- (3-fluorophenyl) piperazin-1-yl) methyl] -5-methylthiophen-3-yl} (4-chlorophenyl) methanone
Claims (28)
R2、R3、及びR4は、互いに独立して、水素、アルキル、置換アルキル、アリール、置換アリール、シクロアルキル、置換シクロアルキル、ハロゲン、ヒドロキシル、ニトロ、シアノ、アルコキシ、又は置換アルコキシであり;
Qは、
R6、及びR7は、互いに独立して、水素、C1−C3アルキル、又はC1−C3置換アルキルであるか、又は
R6、及びR7が同じ炭素原子に結合している場合は、これらに結合している炭素原子とアルキレン結合して3〜7員のスピロシクロ環を形成し;
R8、R9、R10、R11、R12、及びR13は、互いに独立して、水素、C1−C3アルキル、又はC1−C3置換アルキルであり;
Xは、N又はC−Hであるか、又は
Xは、C−NR14R15(ここにおいて、R14及びR15は、互いに独立して、水素、C1−C3アルキル、C1−C3置換アルキル、アリール、又は置換アリールである)であるか、又は
Xは、C−R16(ここにおいて、R16及びR5は結合してカルボニル酸素である)であるか、又は
Xは、C−R16(ここにおいて、結合したR16及びR5は、R16及びR5に結合している炭素原子と5〜7員のスピロシクロ環を形成する式:
R17及びR18は、互いに独立して、水素、C1−C6アルキル、C1−C6置換アルキル、シクロアルキル、置換シクロアルキル、アリール、又は置換アリールであり;
nは、0、又は1若しくは2の整数である)
の2価の基である)であるか、又は
Xは、C−R16(ここにおいて、結合したR16及びR5は、R16及びR5に結合している炭素原子と5員のスピロシクロ環を形成する式:
R19及びR20は、互いに独立して、水素、ハロゲン、シアノ、トリフルオロメチル、C1−C6アルキル、C1−C6置換アルキル、又はC1−C6アルコキシである)の2価の基である)よりなる群から選ばれる]:
の化合物又はその薬学的に許容される塩。 Formula (I)
R 2 , R 3 , and R 4 are independently of each other hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, nitro, cyano, alkoxy, or substituted alkoxy ;
Q is
R 6 and R 7 are independently of each other hydrogen, C 1 -C 3 alkyl, or C 1 -C 3 substituted alkyl, or R 6 and R 7 are bonded to the same carbon atom. In some cases, alkylene bonds with the carbon atoms attached to them form a 3-7 membered spirocyclo ring;
R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 are each independently hydrogen, C 1 -C 3 alkyl, or C 1 -C 3 substituted alkyl;
X is N or C—H, or X is C—NR 14 R 15 (wherein R 14 and R 15 independently of one another are hydrogen, C 1 -C 3 alkyl, C 1 — X is C 3 -substituted alkyl, aryl, or substituted aryl), or X is C—R 16 (wherein R 16 and R 5 are combined and are a carbonyl oxygen), or X is in C-R 16 (wherein, the bound R 16 and R 5, wherein forming the Supiroshikuro ring carbon atoms and 5-7 membered bonded to R 16 and R 5:
R 17 and R 18 are independently of each other hydrogen, C 1 -C 6 alkyl, C 1 -C 6 substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl;
n is 0 or an integer of 1 or 2)
Whether it is of a divalent group), or X is C-R 16 (wherein, the bound R 16 and R 5, Supiroshikuro carbon atoms and 5-membered bonded to R 16 and R 5 Formula that forms a ring:
R 19 and R 20 are each independently hydrogen, halogen, cyano, trifluoromethyl, C 1 -C 6 alkyl, C 1 -C 6 substituted alkyl, or C 1 -C 6 alkoxy) Selected from the group consisting of:
Or a pharmaceutically acceptable salt thereof.
R6、及びR7は、互いに独立して、水素、C1−C3アルキル、又はC1−C3置換アルキルであるか、又は
R6、及びR7が同じ炭素原子に結合している場合は、これらに結合している炭素原子とアルキレン結合して3〜7員のスピロシクロ環を形成し;
Xは、N又はC−Hであるか、又は
Xは、C−NR14R15(ここにおいて、R14及びR15は、互いに独立して、水素、C1−C3アルキル、C1−C3置換アルキル、アリール、又は置換アリールである)であるか、又は
Xは、C−R16(ここにおいて、R16及びR5は結合してカルボニル酸素である)であるか、又は
Xは、C−R16(ここにおいて、結合したR16及びR5は、R16及びR5に結合している炭素原子と5〜7員のスピロシクロ環を形成する式:
R17及びR18は、互いに独立して、水素、C1−C6アルキル、C1−C6置換アルキル、シクロアルキル、置換シクロアルキル、アリール、又は置換アリールであり;
nは、0、又は1若しくは2の整数である)
の2価の基である)であるか、又は
Xは、C−R16(ここにおいて、結合したR16及びR5は、R16及びR5に結合している炭素原子と5員のスピロシクロ環を形成する式:
R19及びR20は、互いに独立して、水素、ハロゲン、シアノ、トリフルオロメチル、C1−C6アルキル、C1−C6置換アルキル、又はC1−C6アルコキシである)の2価の基)である、請求項1又は2に記載の化合物又はその薬学的に許容される塩。 Q is
R 6 and R 7 are independently of each other hydrogen, C 1 -C 3 alkyl, or C 1 -C 3 substituted alkyl, or R 6 and R 7 are bonded to the same carbon atom. In some cases, alkylene bonds with the carbon atoms attached to them form a 3-7 membered spirocyclo ring;
X is N or C—H, or X is C—NR 14 R 15 (wherein R 14 and R 15 independently of one another are hydrogen, C 1 -C 3 alkyl, C 1 — X is C 3 -substituted alkyl, aryl, or substituted aryl), or X is C—R 16 (wherein R 16 and R 5 are combined and are a carbonyl oxygen), or X is in C-R 16 (wherein, the bound R 16 and R 5, wherein forming the Supiroshikuro ring carbon atoms and 5-7 membered bonded to R 16 and R 5:
R 17 and R 18 are independently of each other hydrogen, C 1 -C 6 alkyl, C 1 -C 6 substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl;
n is 0 or an integer of 1 or 2)
Whether it is of a divalent group), or X is C-R 16 (wherein, the bound R 16 and R 5, Supiroshikuro carbon atoms and 5-membered bonded to R 16 and R 5 Formula that forms a ring:
R 19 and R 20 are each independently hydrogen, halogen, cyano, trifluoromethyl, C 1 -C 6 alkyl, C 1 -C 6 substituted alkyl, or C 1 -C 6 alkoxy) Or a pharmaceutically acceptable salt thereof. The compound according to claim 1 or 2 , wherein
R2、R3、及びR4は、互いに独立して、水素、アルキル、置換アルキル、アリール、置換アリール、シクロアルキル、置換シクロアルキル、ハロゲン、ヒドロキシル、ニトロ、シアノ、アルコキシ、又は置換アルコキシであり;
R5は、アルキル、置換アルキル、アリール、置換アリール、シクロアルキル、置換シクロアルキル、ヘテロアリール、置換ヘテロアリール、ヘテロアラルキル、置換ヘテロアラルキル、アシル、又は置換アシルであり;
R6、及びR7は、互いに独立して、水素、C1−C3アルキル、又はC1−C3置換アルキルであるか、又は
R6、及びR7が同じ炭素原子に結合している場合は、これらに結合している炭素原子とアルキレン結合して3〜7員のスピロシクロ環を形成し;
R8、及びR9は、互いに独立して、水素、C1−C3アルキル、又はC1−C3置換アルキルである):
の、請求項4に記載の化合物又はその薬学的に許容される塩。 Formula (IA):
R 2 , R 3 , and R 4 are independently of each other hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, nitro, cyano, alkoxy, or substituted alkoxy ;
R 5 is alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl, acyl, or substituted acyl;
R 6 and R 7 are independently of each other hydrogen, C 1 -C 3 alkyl, or C 1 -C 3 substituted alkyl, or R 6 and R 7 are bonded to the same carbon atom. In some cases, alkylene bonds with the carbon atoms attached to them form a 3-7 membered spirocyclo ring;
R 8 and R 9 are independently of one another hydrogen, C 1 -C 3 alkyl, or C 1 -C 3 substituted alkyl):
Or a pharmaceutically acceptable salt thereof.
R19及びR20は、互いに独立して、水素、ハロゲン、シアノ、トリフルオロメチル、C1−C6アルキル、C1−C6置換アルキル又はC1−C6アルコキシである):
の2価の基である、請求項3に記載の化合物又はその薬学的に許容される塩。 Formula where X is C—R 16 and the bonded R 16 and R 5 form a 5-membered spirocyclo ring with the carbon atom bonded to R 16 and R 5 :
R 19 and R 20 are independently of one another hydrogen, halogen, cyano, trifluoromethyl, C 1 -C 6 alkyl, C 1 -C 6 substituted alkyl or C 1 -C 6 alkoxy):
The compound or pharmaceutically acceptable salt thereof according to claim 3, which is a divalent group of
R2、R3、及びR4は、互いに独立して、水素、アルキル、置換アルキル、アリール、置換アリール、シクロアルキル、置換シクロアルキル、ハロゲン、ヒドロキシル、ニトロ、シアノ、アルコキシ、又は置換アルコキシであり;
R6、R7、R8及びR9は、互いに独立して、水素、C1−C3アルキル、又はC1−C3置換アルキルであり;
R19及びR20は、互いに独立して、水素、ハロゲン、シアノ、トリフルオロメチル、C1−C6アルキル、C1−C6置換アルキル、又はC1−C6アルコキシである):
の、請求項13に記載の化合物又はその薬学的に許容される塩。 Formula (IB):
R 2 , R 3 , and R 4 are independently of each other hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, nitro, cyano, alkoxy, or substituted alkoxy ;
R 6 , R 7 , R 8 and R 9 are independently of each other hydrogen, C 1 -C 3 alkyl, or C 1 -C 3 substituted alkyl;
R 19 and R 20 are independently of each other hydrogen, halogen, cyano, trifluoromethyl, C 1 -C 6 alkyl, C 1 -C 6 substituted alkyl, or C 1 -C 6 alkoxy):
Of the compound or a pharmaceutically acceptable salt thereof according to claim 13.
{2−アミノ−4−[(4−メチルピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−フルオロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−クロロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−メトキシフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−p−トリルピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(ピリジン−2−イル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(ピリミジン−2−イル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(3,4−ジクロロフェニル)−ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
4−{4−[(5−アミノ−4−(4−クロロベンゾイル)チオフェン−3−イル)メチル]ピペラジン−1−イル}ベンゾニトリル;
{2−アミノ−4−[(4−(3−クロロフェニル)−ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(2−クロロフェニル)−ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(2−フルオロフェニル)−ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(3−(トリフルオロメチル)フェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
1−{4−[(5−アミノ−4−(4−クロロベンゾイル)チオフェン−3−イル)メチル]ピペラジン−1−イル}−2−(4−クロロフェニル)エタノン;
{2−アミノ−4−[(4−(4−クロロベンゾイル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(ピリジン−4−イル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(ベンゾ[d]ジオキソール−5−イル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(2,3−ジクロロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(3−フルオロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(3,5−ジクロロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−(トリフルオロメチル)フェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
2−{4−[(5−アミノ−4−(4−クロロベンゾイル)チオフェン−3−イル)メチル]ピペラジン−1−イル}−1−(4−クロロフェニル)エタノン;
{2−アミノ−4−[(4−(2,4−ジフルオロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(2,6−ジフルオロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(3−クロロ−4−フルオロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−シクロヘキシルピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−クロロフェニル)ピペリジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−ニトロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−イソプロピルピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(ナフタレン−1−イル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(3,4−ジフルオロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−シクロペンチルピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−シクロペンチルピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−クロロベンジル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−ベンジルピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
(2−アミノ−4−{[4−(2−(4−クロロフェニル)エチル)ピペラジン−1−イル]メチル}チオフェン−3−イル)(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−フルオロベンジル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−シクロオクチルピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
(2−アミノ−4−{[4−[3−(4−クロロフェニル)プロピル]ピペラジン−1−イル]メチル}チオフェン−3−イル)(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(2,4−ジクロロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(2,5−ジフルオロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(2−(トリフルオロメチル)フェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−クロロ−3−(トリフルオロメチル)フェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(2,4,6−トリフルオロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(2−クロロ−4−フルオロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(2−フルオロ−4−クロロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(3,5−ジフルオロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(2,6−ジクロロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−(トリフルオロメトキシ)フェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(ピリジン−3−イル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(2,5−ジクロロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(2,3−ジフルオロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−クロロフェニル)−3−メチルピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−(トリフルオロメチル)フェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}[3−(トリフルオロメチル)フェニル]メタノン;
{2−アミノ−4−[(4−(3−フルオロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}[3−(トリフルオロメチル)フェニル]メタノン;
{2−アミノ−4−[(4−(2,6−ジフルオロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}[3−(トリフルオロメチル)フェニル]メタノン;
{2−アミノ−4−(スピロ[ベンゾ[d][1,3]−ジオキソール−2,4’−ピペリジン]−1’−イルメチル)チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−(5−tert−ブチルスピロ[ベンゾ[d][1,3]−ジオキソール−2,4’−ピペリジン]−1’−イルメチル)チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−(4−フルオロスピロ[ベンゾ[d][1,3]−ジオキソール−2,4’−ピペリジン]−1’−イルメチル)チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−(4−メチルスピロ[ベンゾ[d][1,3]−ジオキソール−2,4’−ピペリジン]−1’−イルメチル)チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−(5−メチルスピロ[ベンゾ[d][1,3]−ジオキソール−2,4’−ピペリジン]−1’−イルメチル)チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−クロロフェニルアミノ)ピペリジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−クロロフェニル)メチルアミノ]ピペリジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−クロロフェニル)−[1,4]ジアゼパン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(7−(4−クロロフェニル)−2,7−ジアザ−スピロ[4,4]ノン−2−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(5−(4−クロロフェニル)ヘキサヒドロピロロ[3,4−c]ピロール−2−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(5−(4−クロロフェニル)−2,5−ジアザビシクロ[2,2,1]ヘプタ−2−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−フルオロフェニル)ピペラジン−1−イル)メチル]−5−メチルチオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−5−メチル−4−[(4−フェニルピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−5−メチル−4−[(4−(4−(トリフルオロメチル)フェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−クロロフェニル)ピペラジン−1−イル)メチル]−5−メチルチオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−ブロモフェニル)ピペラジン−1−イル)メチル]−5−メチルチオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−ヨードフェニル)ピペラジン−1−イル)メチル]−5−メチルチオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−5−メチル−4−[(4−(4−ニトロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
4−{4−[(5−アミノ−4−(4−クロロベンゾイル)−2−メチルチオフェン−3−イル)メチル]ピペラジン−1−イル}ベンゾニトリル;
{2−アミノ−4−[(4−ベンジルピペラジン−1−イル)メチル]−5−メチルチオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−メトキシフェニル)ピペラジン−1−イル)メチル]−5−メチルチオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−5−メチル−4−[(4−p−トリルピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(3,4−ジクロロフェニル)ピペラジン−1−イル)メチル]−5−メチル−チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−5−メチル−4−[(4−(3−(トリフルオロメチル)フェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(3−クロロフェニル)ピペラジン−1−イル)メチル]−5−メチルチオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−クロロ−3−(トリフルオロメチル)フェニル)ピペラジン−1−イル)メチル]−5−メチルチオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−5−フェニル−4−[(ピペリジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−フルオロフェニル)ピペラジン−1−イル)メチル]−5−エチルチオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−5−エチル−4−[(4−フェニルピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
{2−アミノ−4−[(4−(4−クロロフェニル)ピペラジン−1−イル)メチル]−5−エチルチオフェン−3−イル}(4−クロロフェニル)メタノン;及び
{2−アミノ−4−[(4−(3−フルオロフェニル)ピペラジン−1−イル)メチル]−5−メチルチオフェン−3−イル}(4−クロロフェニル)メタノン;
よりなる群から選ばれる、請求項1に記載の化合物又はその薬学的に許容される塩。 {2-amino-4-[(4-phenylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4-methylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-fluorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-chlorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-methoxyphenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4-p-tolylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (pyridin-2-yl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (pyrimidin-2-yl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (3,4-dichlorophenyl) -piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
4- {4-[(5-amino-4- (4-chlorobenzoyl) thiophen-3-yl) methyl] piperazin-1-yl} benzonitrile;
{2-amino-4-[(4- (3-chlorophenyl) -piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (2-chlorophenyl) -piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (2-fluorophenyl) -piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (3- (trifluoromethyl) phenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
1- {4-[(5-amino-4- (4-chlorobenzoyl) thiophen-3-yl) methyl] piperazin-1-yl} -2- (4-chlorophenyl) ethanone;
{2-amino-4-[(4- (4-chlorobenzoyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (pyridin-4-yl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (benzo [d] dioxol-5-yl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (2,3-dichlorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (3-fluorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (3,5-dichlorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4- (trifluoromethyl) phenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
2- {4-[(5-amino-4- (4-chlorobenzoyl) thiophen-3-yl) methyl] piperazin-1-yl} -1- (4-chlorophenyl) ethanone;
{2-amino-4-[(4- (2,4-difluorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (2,6-difluorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (3-chloro-4-fluorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4-cyclohexylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-chlorophenyl) piperidin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-nitrophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4-isopropylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (naphthalen-1-yl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (3,4-difluorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4-cyclopentylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4-cyclopentylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-chlorobenzyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4-benzylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
(2-amino-4-{[4- (2- (4-chlorophenyl) ethyl) piperazin-1-yl] methyl} thiophen-3-yl) (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-fluorobenzyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4-cyclooctylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
(2-amino-4-{[4- [3- (4-chlorophenyl) propyl] piperazin-1-yl] methyl} thiophen-3-yl) (4-chlorophenyl) methanone;
{2-amino-4-[(4- (2,4-dichlorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (2,5-difluorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (2- (trifluoromethyl) phenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-chloro-3- (trifluoromethyl) phenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (2,4,6-trifluorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (2-chloro-4-fluorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (2-fluoro-4-chlorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (3,5-difluorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (2,6-dichlorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4- (trifluoromethoxy) phenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (pyridin-3-yl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (2,5-dichlorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (2,3-difluorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-chlorophenyl) -3-methylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4- (trifluoromethyl) phenyl) piperazin-1-yl) methyl] thiophen-3-yl} [3- (trifluoromethyl) phenyl] methanone;
{2-amino-4-[(4- (3-fluorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} [3- (trifluoromethyl) phenyl] methanone;
{2-amino-4-[(4- (2,6-difluorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} [3- (trifluoromethyl) phenyl] methanone;
{2-amino-4- (spiro [benzo [d] [1,3] -dioxol-2,4′-piperidine] -1′-ylmethyl) thiophen-3-yl} (4-chlorophenyl) methanone;
{2-Amino-4- (5-tert-butylspiro [benzo [d] [1,3] -dioxol-2,4′-piperidine] -1′-ylmethyl) thiophen-3-yl} (4-chlorophenyl) Methanone;
{2-amino-4- (4-fluorospiro [benzo [d] [1,3] -dioxol-2,4'-piperidin] -1'-ylmethyl) thiophen-3-yl} (4-chlorophenyl) methanone ;
{2-amino-4- (4-methylspiro [benzo [d] [1,3] -dioxol-2,4′-piperidine] -1′-ylmethyl) thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4- (5-methylspiro [benzo [d] [1,3] -dioxol-2,4′-piperidin] -1′-ylmethyl) thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-chlorophenylamino) piperidin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-chlorophenyl) methylamino] piperidin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-chlorophenyl)-[1,4] diazepan-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(7- (4-chlorophenyl) -2,7-diaza-spiro [4,4] non-2-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(5- (4-chlorophenyl) hexahydropyrrolo [3,4-c] pyrrol-2-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(5- (4-chlorophenyl) -2,5-diazabicyclo [2,2,1] hept-2-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-fluorophenyl) piperazin-1-yl) methyl] -5-methylthiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-5-methyl-4-[(4-phenylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-5-methyl-4-[(4- (4- (trifluoromethyl) phenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-chlorophenyl) piperazin-1-yl) methyl] -5-methylthiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-bromophenyl) piperazin-1-yl) methyl] -5-methylthiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-iodophenyl) piperazin-1-yl) methyl] -5-methylthiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-5-methyl-4-[(4- (4-nitrophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
4- {4-[(5-amino-4- (4-chlorobenzoyl) -2-methylthiophen-3-yl) methyl] piperazin-1-yl} benzonitrile;
{2-amino-4-[(4-benzylpiperazin-1-yl) methyl] -5-methylthiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-methoxyphenyl) piperazin-1-yl) methyl] -5-methylthiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-5-methyl-4-[(4-p-tolylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (3,4-dichlorophenyl) piperazin-1-yl) methyl] -5-methyl-thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-5-methyl-4-[(4- (3- (trifluoromethyl) phenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (3-chlorophenyl) piperazin-1-yl) methyl] -5-methylthiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-chloro-3- (trifluoromethyl) phenyl) piperazin-1-yl) methyl] -5-methylthiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-5-phenyl-4-[(piperidin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-fluorophenyl) piperazin-1-yl) methyl] -5-ethylthiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-5-ethyl-4-[(4-phenylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-chlorophenyl) piperazin-1-yl) methyl] -5-ethylthiophen-3-yl} (4-chlorophenyl) methanone; and {2-amino-4- [ (4- (3-Fluorophenyl) piperazin-1-yl) methyl] -5-methylthiophen-3-yl} (4-chlorophenyl) methanone;
The compound according to claim 1 or a pharmaceutically acceptable salt thereof selected from the group consisting of:
{2−アミノ−4−[(4−(4−クロロフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;及び
{2−アミノ−4−[(4−(4−トリフルオロメチルフェニル)ピペラジン−1−イル)メチル]チオフェン−3−イル}(4−クロロフェニル)メタノン;
よりなる群から選ばれる、請求項1に記載の化合物又はその薬学的に許容される塩。 {2-amino-4-[(4-phenylpiperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
{2-amino-4-[(4- (4-chlorophenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone; and {2-amino-4-[(4- ( 4-trifluoromethylphenyl) piperazin-1-yl) methyl] thiophen-3-yl} (4-chlorophenyl) methanone;
The compound according to claim 1 or a pharmaceutically acceptable salt thereof selected from the group consisting of:
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85850506P | 2006-11-13 | 2006-11-13 | |
US11/938,514 US7897596B2 (en) | 2006-11-13 | 2007-11-12 | Allosteric modulators of the A1 adenosine receptor |
US11/938,465 US7855209B2 (en) | 2006-11-13 | 2007-11-12 | Allosteric modulators of the A1 adenosine receptor |
PCT/US2007/084490 WO2008063984A2 (en) | 2006-11-13 | 2007-11-13 | Allosteric modulators of the a1 adenosine receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010509402A JP2010509402A (en) | 2010-03-25 |
JP2010509402A5 true JP2010509402A5 (en) | 2011-01-06 |
Family
ID=39430473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009537305A Withdrawn JP2010509402A (en) | 2006-11-13 | 2007-11-13 | Allosteric modulator of A1 adenosine receptor |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2081575A4 (en) |
JP (1) | JP2010509402A (en) |
KR (1) | KR20090112627A (en) |
AU (1) | AU2007323888A1 (en) |
BR (1) | BRPI0718520A2 (en) |
CA (1) | CA2669447A1 (en) |
IL (1) | IL198402A0 (en) |
MX (1) | MX2009004763A (en) |
WO (1) | WO2008063984A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103739588B (en) * | 2014-01-04 | 2015-07-01 | 新发药业有限公司 | Simple synthesis method of 2-aminothiophene derivative |
EP3736272A1 (en) * | 2015-09-14 | 2020-11-11 | The National Institute for Biotechnology in the Negev Ltd. | Novel piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting vdac oligomerization, apoptosis and mitochondria dysfunction |
US10434099B2 (en) | 2016-09-22 | 2019-10-08 | The National Institute for Biotechnology in the Negev Ltd. | Methods for treating central nervous system disorders using VDAC inhibitors |
US10787423B2 (en) | 2015-09-14 | 2020-09-29 | The National Institute For Biotechnolgy In The Negev Ltd. | Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction |
US11220505B2 (en) | 2017-03-21 | 2022-01-11 | Temple University-Of The Commonwealth System Of Higher Education | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents |
JP7365237B2 (en) * | 2017-03-21 | 2023-10-19 | テンプル・ユニバーシティ-オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | Novel modulators of sigma-2 receptors and methods for their use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5332732A (en) * | 1992-09-11 | 1994-07-26 | Mcneilab, Inc. | Thiophene and pyridine antipsychotic agents |
DE59303357D1 (en) * | 1992-10-29 | 1996-09-05 | Hoechst Ag | Process for the preparation of aromatic bromomethyl compounds |
US5939432A (en) * | 1997-10-29 | 1999-08-17 | Medco Research, Inc. | Thiophenes useful for modulating the adenosine receptor |
-
2007
- 2007-11-13 KR KR1020097009765A patent/KR20090112627A/en not_active Application Discontinuation
- 2007-11-13 AU AU2007323888A patent/AU2007323888A1/en not_active Abandoned
- 2007-11-13 MX MX2009004763A patent/MX2009004763A/en not_active Application Discontinuation
- 2007-11-13 WO PCT/US2007/084490 patent/WO2008063984A2/en active Application Filing
- 2007-11-13 CA CA002669447A patent/CA2669447A1/en not_active Abandoned
- 2007-11-13 EP EP07864306A patent/EP2081575A4/en not_active Withdrawn
- 2007-11-13 BR BRPI0718520-0A patent/BRPI0718520A2/en not_active IP Right Cessation
- 2007-11-13 JP JP2009537305A patent/JP2010509402A/en not_active Withdrawn
-
2009
- 2009-04-26 IL IL198402A patent/IL198402A0/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100357278C (en) | Substituted triazole diamine derivatives as kinase inhibitors | |
TWI510481B (en) | Benzimidazole-proline derivatives | |
IL271149B2 (en) | Compounds for modulating s1p1 activity and methods of using the same | |
JP5080241B2 (en) | Composition comprising JNK inhibitor and scrosporin | |
RU2559895C2 (en) | Nitrogen-containing heteroaryl derivatives | |
JP2010509402A5 (en) | ||
US8859768B2 (en) | Heteroaryls and uses thereof | |
CN104540831B (en) | The difluoro dioxolanes aminobenzimidazole kinase inhibitor disorderly for treating cancer, autoimmune inflammation and CNS | |
JP2010502716A (en) | Modulator of interleukin 1 receptor related kinase | |
US20230059381A1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
JP2017105852A (en) | Use of pde7 inhibitors for treating movement disorders | |
RU2019132212A (en) | SELECTIVE HDAC6 INHIBITORS | |
JPWO2006070943A1 (en) | Condensed imidazole compounds and uses thereof | |
JP2000510870A (en) | Amides as NPY5 receptor antagonists | |
JP2010523497A5 (en) | ||
TW201924676A (en) | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | |
JP2014529628A5 (en) | ||
JP2017014224A (en) | Agent for prevention or treatment of acute-phase pain in herpes zoster-related pain | |
CN102272125A (en) | Pyridazinone derivatives | |
CA2425638A1 (en) | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | |
JP5731538B2 (en) | CRTH2 modulator | |
JP2010509402A (en) | Allosteric modulator of A1 adenosine receptor | |
MXPA06004434A (en) | Novel medical uses of compounds showing cb1. | |
KR20010029716A (en) | Combination Therapy for the Treatment of Migraine | |
US8658640B2 (en) | JNK inhibitors for the treatment of endometriosis |